Welcome to our dedicated page for Cidara Theraptcs news (Ticker: CDTX), a resource for investors and traders seeking the latest updates and insights on Cidara Theraptcs stock.
Cidara Therapeutics Inc (NASDAQ: CDTX) is a clinical-stage biotechnology company being acquired by Merck & Co. This page archives news coverage for Cidara, tracking developments in its anti-infective drug pipeline and the ongoing acquisition process.
Cidara's news flow centered on its lead program, CD388, a long-acting antiviral for seasonal influenza prevention. Coverage includes clinical trial milestones, FDA interactions including the Breakthrough Therapy Designation, and funding announcements from government agencies like BARDA. The company also generated news related to its Cloudbreak immunotherapy platform and earlier antifungal programs.
With the Merck acquisition underway, this news archive provides valuable context on Cidara's scientific achievements, the strategic rationale behind the deal, and the company's contributions to anti-infective research. Historical news documents the company's progression from early-stage antifungal programs to becoming an acquisition target based on its influenza prevention technology.
Bookmark this page to follow acquisition updates, regulatory filings, and any remaining clinical data releases as Cidara transitions to Merck ownership.
FAQ
What is the current stock price of Cidara Theraptcs (CDTX)?
What is the market cap of Cidara Theraptcs (CDTX)?
